• Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice.
    • Yamai T, Ikezawa K, Sugimoto N, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Kawamura T, Kunimasa K, Yamamoto S, Wakamatsu T, Hayashi T, Kukita Y, Fujisawa F, Inoue T, Yamaguchi Y, Yamasaki T, Honma K, Ohkawa K.
    • Cancers (Basel). 2023 Feb 3;15(3):970. doi: 10.3390/cancers15030970.
    • Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer.
    • King D.
    • OncLive. OncLive TV. 2023 Jan 31.
    • Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
    • Liu J, Mroczek M, Mach A, Stępień M, Aplas A, Pronobis-Szczylik B, Bukowski S, Mielczarek M, Gajewska E, Topolski P, Król ZJ, Szyda J, Dobosz P.
    • Cancers (Basel). 2023 Jan 27;15(3):779. doi: 10.3390/cancers15030779.
    • Implementation of a multi modal best practice bundle to improve genetic testing referral for pancreatic cancer patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Blazey M, Lee T, Hendershot A, Bartell N, Marino D.
    • Fam Cancer. [P-20: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma.
    • Debbabi I, Vacher S, Neuzillet C, Cros J, Revillon F, Petitalot A, Turpin A, Antonio S, Girard E, Dupain C, Kamal M, Hammel P, Bièche I, Masliah-Planchon J, Caputo SM.
    • Ther Adv Med Oncol. 2023 Jan 18;15:17588359221146132. doi: 10.1177/17588359221146132.
    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2022 Dec 21 [2023 Jan 1];179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.
    • Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    • Vera R, Ibarrola-de Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
    • Rev Esp Patol. 2023 Jan-Mar;56(1):32-44. doi: 10.1016/j.patol.2022.06.004. Epub 2022 Aug 26.
    • Review
    • Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
    • Drogan CM, Kindler HL, Gao G, Kupfer SS.
    • JCO Precis Oncol. 2023 Jan;7:e2200196. doi: 10.1200/PO.22.00196.
    • Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
    • Okada K, Uemura K, Okamoto W, Sumiyoshi T, Shintakuya R, Otsuka H, Serikawa M, Ishii Y, Arihiro K, Takahashi S.
    • Clin J Gastroenterol. 2022 Dec 27. doi: 10.1007/s12328-022-01741-2. Epub ahead of print.
    • Case report
    • A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer.
    • Yildirim HC, Ismayilov R, Akyildiz A, Guven DC, Abdurrahimli N, Dizdar O, Yalcin S.
    • Anticancer Drugs. 2022 Dec 19. doi: 10.1097/CAD.0000000000001486. Epub ahead of print.
    • Case report
    • Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma.
    • Huffman BM, Ellis H, Jordan AC, Freed-Pastor WA, Perez K, Rubinson DA, Sethi N, Singh H, Surana R, Wolpin BM, Aguirre AJ, Cleary JM.
    • Cancers (Basel). 2022 Dec 16;14(24):6223. doi: 10.3390/cancers14246223.
    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.
    • Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
    • Lelong M, Raoul JL, Touchefeu Y, Berthelot JM, Arnolfo P, Matysiak-Budnik T, Senellart H.
    • Clin Case Rep. 2022 Dec 12;10(12):e6718. doi: 10.1002/ccr3.6718.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
    • Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Niger M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M.
    • Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02086-w. Epub ahead of print.
    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.
    • Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
    • Lee CL, Holter S, Borgida A, Dodd A, Ramotar S, Grant R, Wasson K, Elimova E, Jang RW, Moore M, Kim TK, Khalili K, Moulton CA, Gallinger S, O'Kane GM, Knox JJ.
    • World J Gastroenterol. 2022 Dec 7;28(45):6421-6432. doi: 10.3748/wjg.v28.i45.6421.
    • NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer.
    • Jung K, Lee S, Na HY, Kim JW, Lee JC, Hwang JH, Kim JW, Kim J.
    • Sci Rep. 2022 Dec 3;12(1):20937. doi: 10.1038/s41598-022-24732-2.
    • Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome.
    • Tsuneizumi M, Terada S, Usui T, Yamaguchi K, Hayami R, Matsunuma R.
    • Oxf Med Case Reports. 2022 Nov 24;2022(11):omac124. doi: 10.1093/omcr/omac124.
    • Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
    • Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H.
    • Expert Opin Pharmacother. 2022 Nov 17. doi: 10.1080/14656566.2022.2149322. Epub ahead of print.
    • Review
    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    Related:

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
    • Rémond MS, Pellat A, Brezault C, Dhooge M, Coriat R.
    • ESMO Open. 2022 Nov 15;7(6):100638. doi: 10.1016/j.esmoop.2022.100638. Epub ahead of print.
    • The Evolving Landscape of Pancreatic Cancer.
    • Krishnan M.
    • JCO Oncol Pract. 2022 Nov 10:OP2200636. doi: 10.1200/OP.22.00636. Epub ahead of print.
    • Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
    • Vera R, Ibarrola-de-Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, Macarulla T, Serrano-Piñol T, Mondéjar R, Madrigal-Rubiales B.
    • Clin Transl Oncol. 2022 Nov;24(11):2107-2119. doi: 10.1007/s12094-022-02873-0. Epub 2022 Aug 25.
    • Platinum-based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): summary of evidence and application in clinical practice.
    • Reinacher-Schick A, Arnold D, Venerito M, Goekkurt E, Kraeft AL, Seufferlein T.
    • Oncol Res Treat. 2022 Oct 28. doi: 10.1159/000527692. Epub ahead of print.
    • Review
    • Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib.
    • Botrus G, Roe D, Jameson GS, Serrano Uson Junior PL, Korn RL, Caldwell L, Bargenquast T, Miller M, Borazanci EH.
    • Biomedicines. 2022 Oct 26;10(11):2705. doi: 10.3390/biomedicines10112705.
    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.
    • Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?
    • Garajová I, Balsano R, Gelsomino F, Leonardi F.
    • Tumori. 2022 Oct 26:3008916221132589. doi: 10.1177/03008916221132589. Epub ahead of print.
    • Case report
    • Unusual dMMR Phenotype Locally Advanced Pancreatic Ductal Adenocarcinoma with Germline and Somatic BRCA2 Mutation in a Jehovah Witness Patient.
    • Copur MS, Tun SM, Vargas L, Merani S, Wedel W, Duckert R, Horn A, Lintel N, Herold D, Lavudi S.
    • Clin Colorectal Cancer. 2022 Oct 23:S1533-0028(22)00106-2. doi: 10.1016/j.clcc.2022.10.002. Epub ahead of print.
    • Case report
    • Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in the treatment of unresectable pancreatic cancer.
    • Du J, Zhu L, Sha H, Zou Z, Zhao L, Shen J, Kong W, Qiu Y, Liu B.
    • Front Oncol. 2022 Oct 18;12:1015232. doi: 10.3389/fonc.2022.1015232.
    • Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer.
    • Terashima T, Morizane C, Ushiama M, Shiba S, Takahashi H, Ikeda M, Mizuno N, Tsuji K, Yasui K, Azemoto N, Satake H, Nomura S, Yachida S, Sugano K, Furuse J.
    • Jpn J Clin Oncol. 2022 Oct 6;52(10):1105-1114. doi: 10.1093/jjco/hyac110.
    • Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
    • Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV.
    • Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172.

    Related:

    Identifier: NCT03148795: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer. (ClinicalTrials.gov)

    • PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
    • Chapin WJ, Reiss KA.
    • Hematol Oncol Clin North Am. 2022 Oct;36(5):1019-1032. doi: 10.1016/j.hoc.2022.07.007. Epub 2022 Sep 23.
    • Review
    • Langzeitremission bei einem Patienten mit metastasiertem Adenokarzinom des Pankreas: Aktuelle Therapiemöglichkeiten und neue Therapiealgorithmen mit Hilfe des Molekularen Tumorboards [Long-term response in advanced pancreatic adenocarcinoma - a case report and literature review].
    • Cura Daball P, Tröger H, Daum S.
    • Z Gastroenterol. 2022 Oct;60(10):1510-1516. German. doi: 10.1055/a-1695-3528. Epub 2021 Dec 14.
    • Case report. [Article in German]
    • Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
    • Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, Capanu M, Mandelker D, Stadler ZK, Birsoy O, Jairam S, Yang C, Li Y, Wong D, Benhamida JK, Ladanyi M, Zhang L, O'Reilly EM.
    • Mol Diagn Ther. 2022 Sep 30. doi: 10.1007/s40291-022-00614-1. Epub ahead of print.
    • Pancreatic Adenocarcinoma Management.
    • Jiang Y, Sohal DPS.
    • JCO Oncol Pract. 2022 Sep 22:OP2200328. doi: 10.1200/OP.22.00328. Epub ahead of print.

    Related:

    Commentary:

    Pancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape.

    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma.
    • Li Y, Zhang K, Peng L, Chen L, Gao H, Chen H.
    • Int J Mol Sci. 2022 Sep 6;23(18):10231. doi: 10.3390/ijms231810231.
    • Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.
    • Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, de Mestier L, Bachet JB, Hammel P.
    • Ther Adv Med Oncol. 2022 Sep 6;14:17588359221118019. doi: 10.1177/17588359221118019.
    • Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review.
    • Kachmazov A, Bolotina L, Kornietskaya A, Kuznetsova O, Ivanov M, Fedenko A.
    • Front Oncol. 2022 Sep 2;12:953908. doi: 10.3389/fonc.2022.953908.
    • A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).
    • Teke ME, Saif A, Ryan CE, Lux SC, Hernandez JM, Reiss KA.
    • Ann Surg Oncol. 2022 Sep;29(9):5375-5376. doi: 10.1245/s10434-022-11917-2. Epub 2022 Jun 6.
    • Imaging PARP with [18F]rucaparib in pancreatic cancer models.
    • Chan CY, Chen Z, Destro G, Veal M, Lau D, O'Neill E, Dias G, Mosley M, Kersemans V, Guibbal F, Gouverneur V, Cornelissen B.
    • Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678. doi: 10.1007/s00259-022-05835-4. Epub 2022 May 26.
    • Role of genetic testing in hepatic, pancreatic, and biliary cancers.
    • Hewitt DB, Aziz H, Brown ZJ, Pawlik TM.
    • Surg Oncol. 2022 Sep;44:101844. doi: 10.1016/j.suronc.2022.101844. Epub 2022 Sep 5.
    • Review
    • Clinico-genomic characterization of ATM and HRD in Pancreas Cancer: Application for Practice.
    • Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, Keane F, Balogun F, Yu KH, Kelsen DP, Crane C, Capanu M, Iacobuzio-Donahue C, O'Reilly EM.
    • Clin Cancer Res. 2022 Aug 30:CCR-22-1483. doi: 10.1158/1078-0432.CCR-22-1483. Epub ahead of print.
    • Current Screening Strategies for Pancreatic Cancer.
    • Vanek P, Urban O, Zoundjiekpon V, Falt P.
    • Biomedicines. 2022 Aug 23;10(9):2056. doi: 10.3390/biomedicines10092056.
    • Moving the Needle on Precision Medicine in Pancreatic Cancer.
    • O'Kane GM, Lowery MA.
    • J Clin Oncol. 2022 Aug 20;40(24):2693-2705. doi: 10.1200/JCO.21.02514. Epub 2022 Jul 15.
    • Review
    • Therapie des metastasierten Pankreaskarzinoms [Treatment of metastatic pancreatic cancer].
    • Heinemann V, Boeck S, Westphalen CB.
    • Inn Med (Heidelb). 2022 Aug;63(8):851-862. German. doi: 10.1007/s00108-022-01334-8. Epub 2022 Jul 6.
    • Review. [Article in German]
    • Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes.
    • Tsumura T, Doi K, Marusawa H.
    • Cancers (Basel). 2022 Jul 28;14(15):3674. doi: 10.3390/cancers14153674.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T.
    • J Clin Oncol. 2022 Jul 14:JCO2101604. doi: 10.1200/JCO.21.01604. Epub ahead of print.
    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    • Casolino R, Corbo V, Beer P, Hwang CI, Paiella S, Silvestri V, Ottini L, Biankin AV.
    • Cancers (Basel). 2022 Jun 30;14(13):3239. doi: 10.3390/cancers14133239.
    • Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    • Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.
    • Fam Cancer. 2022 Jun 17. doi: 10.1007/s10689-022-00300-5. Epub ahead of print.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma.
    • Yim E, Leung D.
    • BMJ Case Rep. 2022 Jun 8;15(6):e249837. doi: 10.1136/bcr-2022-249837.
    • Case report
    • Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes.
    • Gu L, Mehta PP, Rao D, Rotemberg V, Capanu M, Chou J, Lin S, Sigel CS, Busam KJ, Boyce L, Gordon A, O'Reilly EM.
    • Cancer Med. 2022 Jun 6. doi: 10.1002/cam4.4916. Epub ahead of print.
    • Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.
    • Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, Hosein PJ.
    • JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.
    • Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.
    • Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies.
    • ESMO Open. 2022 Jun;7(3):100459. doi: 10.1016/j.esmoop.2022.100459. Epub 2022 May 19.
    • Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options.
    • Ozer M, Ranganathan M, Lecomte N, Schvartzman JM, Walch HS, Chatila WK, Hong J, Carlo MI, Walsh MF, Sheehan M, Mandelker D, Ceyhan-Birsoy O, Maio A, Kemel Y, Iacobuzio-Donahue CA, O'Reilly EM, Yu KH.
    • JCO Precis Oncol. 2022 Jun;6:e2100560. doi: 10.1200/PO.21.00560.
    • Case report
    • Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
    • Keane F, Park W, O'Reilly EM.
    • JCO Precis Oncol. 2022 Jun;6:e2200141. doi: 10.1200/PO.22.00141.

    Related:

    Letter, Reply:

    Reply to F. Keane et al.

    Original research:

    Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways.
    • Yin C, Alqahtani A, Noel MS.
    • Cancers (Basel). 2022 May 25;14(11):2619. doi: 10.3390/cancers14112619.
    • How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.
    • Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E.
    • World J Clin Oncol. 2022 May 24;13(5):417-422. doi: 10.5306/wjco.v13.i5.417.
    • OncoPan®: An NGS-Based Screening Methodology to Identify Molecular Markers for Therapy and Risk Assessment in Pancreatic Ductal Adenocarcinoma.
    • Tibiletti MG, Carnevali I, Pensotti V, Chiaravalli AM, Facchi S, Volorio S, Mariette F, Mariani P, Fortuzzi S, Pierotti MA, Sessa F.
    • Biomedicines. 2022 May 23;10(5):1208. doi: 10.3390/biomedicines10051208.
    • Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values.
    • Amin S, Joo S, Nolte S, Yoo HK, Patel N, Byrnes HF, Costa-Cabral S, Johnson CD.
    • BMC Cancer. 2022 May 20;22(1):563. doi: 10.1186/s12885-022-09661-7.
    • BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms.
    • Devico Marciano N, Kroening G, Dayyani F, Zell JA, Lee FC, Cho M, Valerin JG.
    • Cancers (Basel). 2022 May 16;14(10):2453. doi: 10.3390/cancers14102453.
    • Current and Future Therapies for Pancreatic Ductal Adenocarcinoma.
    • Sally Á, McGowan R, Finn K, Moran BM.
    • Cancers (Basel). 2022 May 13;14(10):2417. doi: 10.3390/cancers14102417.
    • Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.
    • Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D.
    • Front Surg. 2022 May 4;9:866173. doi: 10.3389/fsurg.2022.866173.
    • BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.
    • Abdallah R, Zhao S, Garinet S, Hormigos K, Le Corre D, Cros J, Perez Toralla K, Bats AS, Augustin J, Bachet JB, Taly V, Blons H, Taieb J, Laurent-Puig P.
    • Clin Res Hepatol Gastroenterol. 2022 May;46(5):101880. doi: 10.1016/j.clinre.2022.101880. Epub 2022 Feb 11.
    • Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.
    • Zhao L, Singh V, Ricca A, Lee P.
    • J Med Cases. 2022 May;13(5):240-243. doi: 10.14740/jmc3918. Epub 2022 May 7.
    • Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature.
    • Xu JY, Guan WL, Lu SX, Wei XL, Shi WJ, Ren C, Li YH, Li SP, Qiu MZ, Wang FH.
    • Clin Med Insights Oncol. 2022 Apr 30;16:11795549221090186. doi: 10.1177/11795549221090186.
    • Response in BRCA1 mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX.
    • Campoverde LE, Batalini F, Bulushi Y, Bullock A.
    • BMJ Case Rep. 2022 Apr 29;15(4):e249370. doi: 10.1136/bcr-2022-249370.
    • Case report
    • Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, Domecq C, Bourdel G, Denroche RE, Jang GH, Grant RC, Borgida A, Grünwald BT, Dodd A, Wilson JM, Bourque G, O'Kane GM, Fischer SE, Kron CM, Fiset PO, Omeroglu A, Foulkes WD, Gallinger S, Guiot MC, Gao ZH, Zogopoulos G.
    • Front Oncol. 2022 Apr 25;12:860767. doi: 10.3389/fonc.2022.860767.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
    • Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmaña J.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-17. doi: 10.1200/EDBK_350232.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
    • Cheng X, Zhang B, Guo F, Wu H, Jin X.
    • Mol Oncol. 2022 Apr;16(7):1591-1607. doi: 10.1002/1878-0261.13149. Epub 2021 Dec 17.
    • Molecular Pathology of Pancreatic Cancer.
    • Karamitopoulou E.
    • Cancers (Basel). 2022 Mar 16;14(6):1523. doi: 10.3390/cancers14061523.
    • Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
    • Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, Mikhailovich V, Filipenko M, Menshikova S, Tjulandin S, Pokataev I.
    • Ther Adv Med Oncol. 2022 Mar 15;14:17588359221083050. doi: 10.1177/17588359221083050.
    • Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer.
    • Takano S, Fukasawa M, Shindo H, Takahashi E, Fukasawa Y, Kawakami S, Hayakawa H, Kuratomi N, Kadokura M, Yamaguchi T, Inoue T, Maekawa S, Enomoto N.
    • Cancer Sci. 2022 Mar;113(3):1069-1077. doi: 10.1111/cas.15249. Epub 2022 Jan 10.
    • The role of PARP inhibitors in gastrointestinal cancers.
    • Hanna D, Chopra N, Hochhauser D, Khan K.
    • Crit Rev Oncol Hematol. 2022 Mar;171:103621. doi: 10.1016/j.critrevonc.2022.103621. Epub 2022 Feb 3.
    • Review
    • Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer.
    • Sunkara T, Bandaru SS, Boyilla R, Kunadharaju R, Kukkadapu P, Chennamadhavuni A.
    • Cureus. 2022 Feb 24;14(2):e22575. doi: 10.7759/cureus.22575.
    • VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor.
    • Romeo MA, Gilardini Montani MS, Benedetti R, Arena A, D'Orazi G, Cirone M.
    • Int J Mol Sci. 2022 Feb 18;23(4):2268. doi: 10.3390/ijms23042268.
    • Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.
    • Principe DR.
    • Cancers (Basel). 2022 Feb 11;14(4):897. doi: 10.3390/cancers14040897.
    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.
    • Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling.
    • Ettrich TJ, Sturm N, Güthle M, Hüttner FJ, Perkhofer L.
    • Visc Med. 2022 Feb;38(1):20-29. doi: 10.1159/000521631. Epub 2022 Jan 19.
    • Review
    • An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
    • Prete AA, Procaccio L, Bergamo F, Rasola C, Nappo F, Zagonel V, Lonardi S.
    • Curr Oncol. 2022 Jan 27;29(2):544-550. doi: 10.3390/curroncol29020049.
    • Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.
    • Lundy J, McKay O, Croagh D, Ganju V.
    • JCO Precis Oncol. 2022 Jan [27];6:e2100437. doi: 10.1200/PO.21.00437.

    Related:

    Letter, Commentary:

    Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

    Letter, Reply:

    Reply to F. Keane et al.

    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    Related:

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Kasuga A, Okamoto T, Udagawa S, Mori C, Mie T, Furukawa T, Yamada Y, Takeda T, Matsuyama M, Sasaki T, Ozaka M, Ueki A, Sasahira N.
    • Int J Mol Sci. 2022 Jan 21;23(3):1205. doi: 10.3390/ijms23031205.
    • Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2022 Jan 14.
    • Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation.
    • Wu W, Liu Y, Jin Y, Liu L, Guo Y, Xu M, Hao Q, Li D, Fang W, Zhang A, Zhao P.
    • Front Med (Lausanne). 2022 Jan 13;8:746637. doi: 10.3389/fmed.2021.746637.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients.
    • Park JH, Jo JH, Jang SI, Chung MJ, Park JY, Bang S, Park SW, Song SY, Lee HS, Cho JH.
    • Cancers (Basel). 2022 Jan 4;14(1):236. doi: 10.3390/cancers14010236.
    • Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma.
    • Shoucair S, Baker AR, Yu J.
    • Ann Gastroenterol Surg. 2021 Sep 29 [2022 Jan];6(1):7-16. doi: 10.1002/ags3.12514. eCollection 2022 Jan.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic.
    • Mattiolo P, Kryklyva V, Brosens LA, Mafficini A, Lawlor RT, Milella M, Scarpa A, Corbo V, Luchini C.
    • Expert Opin Ther Targets. 2022 Jan;26(1):1-4. doi: 10.1080/14728222.2022.2021397. Epub 2021 Dec 30.
    • Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer.
    • Rustgi SD, Hilfrank KJ, Kastrinos F.
    • Gastrointest Endosc Clin N Am. 2022 Jan;32(1):1-12. doi: 10.1016/j.giec.2021.09.001.
    • Review
    • FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
    • Wu SQ, Huang SH, Lin QW, Tang YX, Huang L, Xu YG, Wang SP.
    • Pharmacol Res. 2022 Jan;175:106040. doi: 10.1016/j.phrs.2021.106040. Epub 2021 Dec 22.
    • Discovery of Potent and Novel Dual PARP/BRD4 Inhibitors for Efficient Treatment of Pancreatic Cancer.
    • Wang SP, Li Y, Huang SH, Wu SQ, Gao LL, Sun Q, Lin QW, Huang L, Meng LQ, Zou Y, Zhu QH, Xu YG.
    • J Med Chem. 2021 Dec 9;64(23):17413-17435. doi: 10.1021/acs.jmedchem.1c01535. Epub 2021 Nov 23.
    • Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?
    • Sutton TL, Grossberg A, Ey F, O'Reilly EM, Sheppard BC.
    • Cancer Biol Ther. 2021 Dec 2;22(10-12):532-536. doi: 10.1080/15384047.2021.1991739. Epub 2021 Oct 25.
    • Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    • Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, Suehnholz SP, Chakravarty D, Yu KH, Varghese AM, Zervoudakis A, Li J, Ku GY, Park JS, Shcherba M, Harding JJ, Goldberg Z, Abou-Alfa GK, Salo-Mullen EE, Stadler ZK, Iacobuzio-Donahue CA, O'Reilly EM.
    • Cancer. 2021 Dec 1;127(23):4393-4402. doi: 10.1002/cncr.33812. Epub 2021 Aug 5.
    • Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
    • Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS.
    • Clin Cancer Res. 2021 Dec 1;27(23):6314-6322. doi: 10.1158/1078-0432.CCR-21-1789. Epub 2021 Sep 27.
    • Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report.
    • Rubinson D, Wolpin BM, Warsofsky IS, Ryan DP, Perez K, Rahma O, Singh H, Yurgelun MB, Shapiro GI, Aguirre AJ, D'Andrea AD, Cleary JM.
    • J Gastrointest Oncol. 2021 Dec;12(6):3133-3140. doi: 10.21037/jgo-21-197.
    • Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype.
    • Jeong KY, Lee H.
    • World J Gastrointest Oncol. 2021 Nov 15;13(11):1544-1550. doi: 10.4251/wjgo.v13.i11.1544.
    • PARP Inhibitors in Pancreatic Cancer.
    • Brown TJ, Reiss KA.
    • Cancer J. 2021 Nov-Dec 01;27(6):465-475. doi: 10.1097/PPO.0000000000000554.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • BRCA-mutant pancreatic ductal adenocarcinoma.
    • Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M.
    • Br J Cancer. 2021 Nov;125(10):1321-1332. doi: 10.1038/s41416-021-01469-9. Epub 2021 Jul 14.
    • Review
    • Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
    • Assaf I, Mans L, Sakr R, Verset G, Van Laethem JL.
    • Eur J Cancer. 2021 Nov;157:63-67. doi: 10.1016/j.ejca.2021.07.042. Epub 2021 Sep 4.
    • Case report
    • Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma.
    • Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist R, Löhr JM, Gustafsson Liljefors M.
    • JCO Precis Oncol. 2021 Nov;5:974-980. doi: 10.1200/PO.21.00024.
    • Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance.
    • Martínez-Galán J, Rodriguez I, Caba O.
    • World J Gastroenterol. 2021 Oct 21;27(39):6515-6521. doi: 10.3748/wjg.v27.i39.6515.
    • Systemic Therapy for Metastatic Pancreatic Cancer.
    • Ettrich TJ, Seufferlein T.
    • Curr Treat Options Oncol. 2021 Oct 19;22(11):106. doi: 10.1007/s11864-021-00895-4.
    • Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
    • Meng F, Lu L, Tan Y, Duan Q, Lu H.
    • Front Oncol. 2021 Oct 4;11:757965. doi: 10.3389/fonc.2021.757965.
    • Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy.
    • Batra A, Tang PA, Cheung WY.
    • Am J Clin Oncol. 2021 Oct 1;44(10):519-525. doi: 10.1097/COC.0000000000000856.
    • Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
    • Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M.
    • ESMO Open. 2021 Oct;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub 2021 Aug 13.
    • Pancreatic Acinar Cell Carcinoma with Germline BRCA2 Mutation and Severe Pancreatic Panniculitis: A Case Report.
    • Dreikhausen L, Schulte N, Belle S, Weidner P, Moersdorf J, Reissfelder C, Ebert MP, Zhan T.
    • Visc Med. 2021 Oct;37(5):447-450. doi: 10.1159/000515267. Epub 2021 Mar 29.
    • Case report
    • Pancreatic Cancer: A Review.
    • Park W, Chawla A, O'Reilly EM.
    • JAMA. 2021 Sep 7;326(9):851-862. doi: 10.1001/jama.2021.13027.
    • Review
    • Hereditary pancreatic cancer.
    • Abe K, Kitago M, Kitagawa Y, Hirasawa A.
    • Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02015-6. Epub ahead of print.
    • Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    • Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T.
    • Cancers (Basel). 2021 Aug 24;13(17):4259. doi: 10.3390/cancers13174259.
    • Targeting DNA damage repair pathways in pancreas cancer.
    • Crowley F, Park W, O'Reilly EM.
    • Cancer Metastasis Rev. 2021 Aug 17. doi: 10.1007/s10555-021-09983-1. Epub ahead of print.
    • Review
    • Das duktale Adenokarzinom des Pankreas: Subtypen und Molekularpathologie [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
    • Schlitter AM, Konukiewitz B, Kasajima A, Reichert M, Klöppel G.
    • Pathologe. 2021 Aug 17. German. doi: 10.1007/s00292-021-00965-2. Epub ahead of print.
    • Review. [Article in German]
    • Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer.
    • Kuo KK, Hsiao PJ, Chang WT, Chuang SC, Yang YH, Wuputra K, Ku CC, Pan JB, Li CP, Kato K, Liu CJ, Wu DC, Yokoyama KK.
    • Cancers (Basel). 2021 Aug 3;13(15):3920. doi: 10.3390/cancers13153920.
    • EUS-based pancreatic cancer surveillance in BRCA1/BRCA2/PALB2/ATM carriers without a family history of pancreatic cancer.
    • Katona BW, Long JM, Ahmad NA, Attalla S, Bradbury AR, Carpenter EL, Clark DF, Constantino G, Das KK, Domchek SM, Dudzik C, Ebrahimzadeh J, Ginsberg GG, Heiman J, Kochman ML, Maxwell KN, McKenna DB, Powers J, Shah PD, Wangensteen KJ, Rustgi AK.
    • Cancer Prev Res (Phila). 2021 Aug 2:canprevres.0161.2021. doi: 10.1158/1940-6207.CAPR-21-0161. Epub ahead of print.
    • Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
    • Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, Hannan ZM, Tondon R, Nathanson K, Vonderheide RH, Wattenberg MM, Beatty G, Domchek SM.
    • J Clin Oncol. 2021 Aug 1;39(22):2497-2505. doi: 10.1200/JCO.21.00003. Epub 2021 May 10.

    Related:

    Research news: Clovis' Rubraca Benefits BRCA1/2, PALB2-Mutated Pancreatic Cancer Patients as Maintenance Therapy. (Precision Oncology News)

    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    • Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M.
    • Cancer Treat Rev. 2021 Jul 23;100:102262. doi: 10.1016/j.ctrv.2021.102262. Epub ahead of print.
    • Review
    • BRCA mutations in pancreatic cancer and progress in their targeting.
    • Alkassis S, Yazdanpanah O, Philip PA.
    • Expert Opin Ther Targets. 2021 Jul 22. doi: 10.1080/14728222.2021.1957462. Epub ahead of print.
    • Review
    • Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.
    • Cleary JM, Wolpin BM, Dougan SK, Raghavan S, Singh H, Huffman B, Sethi NS, Nowak JA, Shapiro GI, Aguirre AJ, D'Andrea AD.
    • Clin Cancer Res. 2021 Jul 20:clincanres.1367.2021. doi: 10.1158/1078-0432.CCR-21-1367. Epub ahead of print.
    • Review
    • The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    • Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D.
    • J Transl Med. 2021 Jul 12;19(1):301. doi: 10.1186/s12967-021-02972-6.
    • Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives.
    • Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R.
    • Ther Adv Med Oncol. 2021 Jul 6;13:17588359211018539. doi: 10.1177/17588359211018539.
    • Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma.
    • Grzelak D.
    • J Adv Pract Oncol. 2021 Jul;12(5):488-491. doi: 10.6004/jadpro.2021.12.5.4. Epub 2021 Jul 1.
    • Recent advances in precision medicine for pancreatic ductal adenocarcinoma.
    • Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H.
    • Ann Gastroenterol Surg. 2021 Feb 3;5(4):457-466. doi: 10.1002/ags3.12436. eCollection 2021 Jul.
    • Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    • Kim SH, Kang CM.
    • Ann Hepatobiliary Pancreat Surg. 2021 Jun 30;25(Suppl 1):S149. doi: 10.14701/ahbps.BP-PP-1-2.
    • How mutations in pancreatic cancer are treated- Is surgery the only option?
    • Gupta T, Su WP.
    • Ann Hepatobiliary Pancreat Surg. 2021 Jun 30;25(Suppl 1):S381. doi: 10.14701/ahbps.EP-182.
    • Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series.
    • Bruno R, Sensi E, Lupi C, Giordano M, Bernardini L, Vivaldi C, Fornaro L, Vasile E, Campani D, Fontanini G.
    • Diagnostics (Basel). 2021 Jun 7;11(6):1046. doi: 10.3390/diagnostics11061046.
    • Expanded Role for PARP Inhibitors in Pancreatic Cancer?
    • [No author given]
    • Cancer Discov. 2021 Jun 3. doi: 10.1158/2159-8290.CD-NB2021-0352. Epub ahead of print.
    • Research news, Review
    • Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.
    • Hoefer RA, Obiora C, Azab B, Harden EA, Kessler JF.
    • Int J Surg Case Rep. 2021 Jun;83:106047. doi: 10.1016/j.ijscr.2021.106047. Epub 2021 May 29.
    • The role of PARP inhibitors in BRCA mutated pancreatic cancer.
    • Chi J, Chung SY, Parakrama R, Fayyaz F, Jose J, Saif MW.
    • Therap Adv Gastroenterol. 2021 May 10;14:17562848211014818. doi: 10.1177/17562848211014818.
    • BRCA mutated pancreatic cancer: A change is coming.
    • Rosen MN, Goodwin RA, Vickers MM.
    • World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943.
    • Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    • Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T.
    • JAMA Oncol. 2021 May 1;7(5):693-699. doi: 10.1001/jamaoncol.2021.0006.
    • Treatment landscape of metastatic pancreatic cancer.
    • De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M.
    • Cancer Treat Rev. 2021 May;96:102180. doi: 10.1016/j.ctrv.2021.102180. Epub 2021 Mar 17.
    • Review
    • Pancreas cancer: Therapeutic trials in metastatic disease.
    • Smithy JW, O'Reilly EM.
    • J Surg Oncol. 2021 May;123(6):1475-1488. doi: 10.1002/jso.26359.
    • Review
    • The Efficacy of Combined Cisplatin and Nanoparticle Albumin-Bound Paclitaxel in a Stage IV Pancreatic Squamous Cell Carcinoma Patient With a Somatic BRCA2 Mutation: A Case Report.
    • Huang X, Wang C, Ma T, Huang Z, Zhou H, Xu L, Zhang R, Zhao J, Zhang Y, Huang Z, Shao L, Wang Y, Yang F, Che X.
    • Front Oncol. 2021 Apr 29;11:585983. doi: 10.3389/fonc.2021.585983.
    • Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer.
    • Reiss KA, Vonderheide RH.
    • Clin Cancer Res. 2021 Apr 23:clincanres.0612.2021. doi: 10.1158/1078-0432.CCR-21-0612. Epub ahead of print.
    • Perspective, Review
    • DNA damage response and repair in pancreatic cancer development and therapy.
    • Rahnamay Farnood P, Danesh Pazhooh R, Asemi Z, Yousefi B.
    • DNA Repair (Amst). 2021 Apr 15;103:103116. doi: 10.1016/j.dnarep.2021.103116. Epub ahead of print.
    • Review
    • Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
    • Golan T, Hammel P.
    • J Natl Compr Canc Netw. 2021 Apr 1;19(4):469-473. doi: 10.6004/jnccn.2021.7031.
    • Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
    • Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A.
    • Cancers (Basel). 2021 Mar 31;13(7):1612. doi: 10.3390/cancers13071612. Erratum in: Cancers (Basel). 2021 Jul 22;13(15):3687.
    • Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?
    • Cortesi L, Piombino C, Toss A.
    • J Pers Med. 2021 Mar 28;11(4):245. doi: 10.3390/jpm11040245.

    Related:

    Original research:

    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

    Original research:

    Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.

    • Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level.
    • Zimmermann MT, Mathison AJ, Stodola T, Evans DB, Abrudan JL, Demos W, Tschannen M, Aldakkak M, Geurts J, Lomberk G, Tsai S, Urrutia R.
    • Front Oncol. 2021 Mar 5;11:606820. doi: 10.3389/fonc.2021.606820.
    • Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.
    • Giannis D, Moris D, Barbas AS.
    • Cancers (Basel). 2021 Mar 3;13(5):1071. doi: 10.3390/cancers13051071
    • Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.
    • Lee MS, Pant S.
    • Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-13. doi: 10.1200/EDBK_321255.
    • Patient-derived xenograft models of BRCA-associated pancreatic cancers.
    • Golan T, Atias D, Stossel C, Raitses-Gurevich M.
    • Adv Drug Deliv Rev. 2021 Feb 19:S0169-409X(21)00044-2. doi: 10.1016/j.addr.2021.02.010. Epub ahead of print.
    • Review
    • Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
    • Kim SH, Hwang HK, Lee WJ, Kang CM.
    • Pancreatology. 2021 Feb 14:S1424-3903(21)00057-0. doi: 10.1016/j.pan.2021.02.007. Epub ahead of print.
    • Pancreatic ductal adenocarcinoma in the era of precision medicine.
    • Zheng-Lin B, O'Reilly EM.
    • Semin Oncol. 2021 Feb 11:S0093-7754(21)00005-1. doi: 10.1053/j.seminoncol.2021.01.005. Epub ahead of print.
    • Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer.
    • Kato S.
    • Diagnostics (Basel). 2021 Feb 6;11(2):252. doi: 10.3390/diagnostics11020252.
    • Diagnostik und Therapie des Pankreaskarzinoms [Diagnostics and therapy of pancreatic carcinoma].
    • Wenzel P, von Figura G.
    • Dtsch Med Wochenschr. 2021 Feb;146(4):246-252. German. doi: 10.1055/a-1221-7306. Epub 2021 Feb 16.
    • Review, [Article in German]
    • Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
    • Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB.
    • JCO Oncol Pract. 2021 Feb;17(2):e236-e247. doi: 10.1200/OP.20.00678. Epub 2021 Jan 13.
    • Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation.
    • Waissi W, Nicol A, Jung M, Rousseau M, Jarnet D, Noel G, Burckel H.
    • Cancers (Basel). 2021 Jan 30;13(3):527. doi: 10.3390/cancers13030527.
    • Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golan T, O'Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH, Stossel C, Atias D, Halperin S, Berger R, Glick Y, Patrick Park JY, Cuggia A, Williamson L, Wong HL, Schaeffer DF, Renouf DJ, Borgida A, Dodd A, Wilson JM, Fischer SE, Notta F, Knox JJ, Zogopoulos G, Gallinger S.
    • Gastroenterology. 2021 Jan 29:S0016-5085(21)00326-7. doi: 10.1053/j.gastro.2021.01.220. Epub ahead of print.
    • CHEK2 mutation in a patient with pancreatic adenocarcinoma-a rare case report.
    • Vittal A, Saha D, Samanta I, Kasi A.
    • AME Case Rep. 2021 Jan 25;5:5. doi: 10.21037/acr-20-83.
    • Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.
    • Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC.
    • Cancers (Basel). 2021 Jan 8;13(2):E198. doi: 10.3390/cancers13020198.
    • A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
    • Wang D, Guan R, Tao Q, Liu S, Yu M, Li X.
    • BMC Med Genomics. 2021 Jan 6;14(1):6. doi: 10.1186/s12920-020-00850-6.
    • A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.
    • Correa T, Laux DE, Hoffman HT.
    • Clin Case Rep. 2020 Nov 25;9(1):429-432. doi: 10.1002/ccr3.3548. eCollection 2021 Jan.
    • Correlazioni tra carcinoma pancreatico e pregresse neoplasie [Correlations between pancreatic carcinoma and previous neoplasms.].
    • Gavazzi F, Giordano L, Nebbia M, Luberto A, Izzo A, Zerbi A.
    • Recenti Prog Med. 2021 Jan;112(1):81-88. Italian. doi: 10.1701/3525.35128.
    • [Article in Italian]
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    • Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos J, Jäger D, Siveke J, Springfeld C.
    • Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Epub ahead of print.
    • Review
    • Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit.
    • Kanski A.
    • Precision Oncology News. 2020 Dec 17.
    • Research news

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    • Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q.
    • Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169.
    • Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma.
    • Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom TH, Petersen GM, Couch FJ, McWilliams RR.
    • Clin Cancer Res. 2020 Dec 15;26(24):6505-6512. doi: 10.1158/1078-0432.CCR-20-1788. Epub 2020 Oct 7.

    Related:

    Commentary, Review:

    Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

    • Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
    • Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R.
    • World J Gastrointest Oncol. 2020 Dec 15;12(12):1456-1463. doi: 10.4251/wjgo.v12.i12.1456.
    • Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    • Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W.
    • J Pancreat Cancer. 2020 Dec 4;6(1):107-115. doi: 10.1089/pancan.2020.0010.
    • Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer.
    • Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    • Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Epub ahead of print.
    • Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    • Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.
    • Food Chem Toxicol. 2020 Nov 30:111892. doi: 10.1016/j.fct.2020.111892. Epub ahead of print.
    • Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed.
    • Nelson R.
    • Medscape. Medical News. 2020 Nov 19.

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
    • Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G.
    • Cancers (Basel). 2020 Nov 12;12(11):E3346. doi: 10.3390/cancers12113346.
    • Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Wu B, Shi L.
    • J Natl Compr Canc Netw. 2020 Nov 2;18(11):1528-1536. doi: 10.6004/jnccn.2020.7587.

    Related:

    Press: Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed. (Medscape)

    Research news: Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit. (Precision Oncology News)

    • Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
    • Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G.
    • ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.
    • An evaluation of olaparib for the treatment of pancreatic cancer.
    • Vaishampayan UN.
    • Expert Opin Pharmacother. 2020 Oct 23. doi: 10.1080/14656566.2020.1837113. Epub ahead of print.
    • Review
    • BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
    • Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.
    • Pancreas. 2020 Oct 2. doi: 10.1097/MPA.0000000000001672. Epub ahead of print.
    • Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.
    • Pokataev I, Fedyanin M, Polyanskaya E, Popova A, Agafonova J, Menshikova S, Tryakin A, Rumyantsev A, Tjulandin S.
    • ESMO Open. 2020;5(1):e000578. doi: 10.1136/esmoopen-2019-000578. Epub 2020 Sep 30.
    • Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes.
    • Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, Endo M, Sugano K, Yoshida T, Murakami Y, Nakagawa H, Spurdle AB, Momozawa Y.
    • EBioMedicine. 2020 Sep 24;60:103033. doi: 10.1016/j.ebiom.2020.103033. Epub ahead of print.
    • PARP inhibition in treatment of pancreatic cancer.
    • Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M.
    • Expert Rev Anticancer Ther. 2020 Sep 16:1-7. doi: 10.1080/14737140.2020.1820330. Epub ahead of print.
    • Review
    • Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    • Hilmi M, Neuzillet C.
    • Bull Cancer. 2020 Sep 14:S0007-4551(20)30324-6. French. doi: 10.1016/j.bulcan.2020.06.009. Epub ahead of print.
    • Letter, News, [Article in French]
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
    • Kimura R, Ohtsuka T, Kubo M, Kajihara A, Fujii A, Watanabe Y, Mori Y, Ikenaga N, Nakata K, Shindo K, Ohuchida K, Nakamura M.
    • Surg Today. 2020 Sep 4. doi: 10.1007/s00595-020-02123-2. Epub ahead of print.
    • Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
    • Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
    • Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.
    • DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    • Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A.
    • Gut. 2020 Aug 27:gutjnl-2019-319984. doi: 10.1136/gutjnl-2019-319984. Epub ahead of print.
    • A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.
    • Verdaguer H, Acosta D, Macarulla T.
    • Future Oncol. 2020 Aug 17. doi: 10.2217/fon-2020-0334. Epub ahead of print.
    • Review
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.
    • Premnath N, O'Reilly EM.
    • Chin Clin Oncol. 2020 Aug 10:cco-2019-ddp-05. doi: 10.21037/cco-2019-ddp-05. Epub ahead of print.
    • Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
    • Macklin-Mantia SK, Hines SL, Kasi PM.
    • Hered Cancer Clin Pract. 2020 Aug 10;18:17. doi: 10.1186/s13053-020-00148-9.
    • Metastatic Pancreatic Cancer: ASCO Guideline Update.
    • Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D.
    • J Clin Oncol. 2020 Aug 5:JCO2001364. doi: 10.1200/JCO.20.01364. Epub ahead of print.
    • Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
    • Pimenta JR, Ueda SKN, Peixoto RD.
    • Case Rep Oncol. 2020 Jul 29;13(2):904-910. doi: 10.1159/000508533.
    • Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward.
    • Franck C, Müller C, Rosania R, Croner RS, Pech M, Venerito M.
    • Cancers (Basel). 2020 Jul 18;12(7):E1955. doi: 10.3390/cancers12071955.
    • A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
    • Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR.
    • Clin Cancer Res. 2020 Jul 15:clincanres.1301.2020. doi: 10.1158/1078-0432.CCR-20-1301. Epub ahead of print.
    • Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors.
    • Hammel P, Vitellius C, Boisteau É, Wisniewski M, Colle E, Hilmi M, Dengremont C, Granier S, Turpin A, de Mestier L, Neuzillet C.
    • Ther Adv Med Oncol. 2020 Jul 9;12:1758835920937949. doi: 10.1177/1758835920937949.
    • Synthetic Lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    • Hu Y, Guo M.
    • Cancer Sci. 2020 Jul 8. doi: 10.1111/cas.14565. Epub ahead of print.
    • PARP Inhibitor Lynparza Receives EU Approval for Germline BRCA-Mutated Pancreatic Cancer.
    • [No author given.]
    • Precision Oncology News. 2020 Jul 8.
    • Pancreatic cancer.
    • Mizrahi JD, Surana R, Valle JW, Shroff RT.
    • Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.
    • Review
    • Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.
    • Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y, Peng L, Yang L.
    • BMC Gastroenterol. 2020 Jun 26;20(1):202. doi: 10.1186/s12876-020-01351-7.
    • Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
    • McAllister F, Maitra A, Burton M, McGuire M..
    • Medscape. 2020 Jun 25.
    • Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
    • Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J.
    • Int J Clin Oncol. 2020 Jun 13. doi: 10.1007/s10147-020-01721-x. Epub ahead of print.
    • Identifying Patients With Pancreatic Cancer Likely to Respond.
    • Harrison P.
    • Medscape. 2020 Jun 2.

    Related:

    Original research:

    Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

    • CHMP Issues Positive Opinion for Lynparza as Maintenance Treatment in BRCA-Mutated Pancreatic Cancer.
    • [No author given]
    • Precision Oncology News. 2020 Jun 1.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
    • Nishikawa G, Booth C, Prasad V.
    • Cancer. 2020 May 27. doi: 10.1002/cncr.32979. Epub ahead of print.
    • Commentary
    • Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    • Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, Balachandran V, McIntyre CA, El Dika I, Khalil DN, Harding JJ, Ghalehsari N, McKinnell Z, Chalasani SB, Makarov V, Selenica P, Pei X, Lecomte N, Kelsen DP, Abou-Alfa GK, Robson ME, Zhang L, Berger MF, Schultz N, Chan TA, Powell SN, Reis-Filho JS, Iacobuzio-Donahue CA, Riaz N, O'Reilly EM.
    • Clin Cancer Res. 2020 May 22. doi: 10.1158/1078-0432.CCR-20-0418. Epub ahead of print.
    • Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?
    • Fazio N.
    • J Clin Oncol. 2020 May 14:JCO2000419. doi: 10.1200/JCO.20.00419. Epub ahead of print.

    Related:

    Original research:

    Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

    • [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
    • Damanakis AI, Gebauer F, Bruns CJ. Molekulare Prädiktoren für den Krankheitsverlauf und die individualisierte Therapie beim Pankreaskarzinom
    • Chirurg. 2020 May 13. German. doi: 10.1007/s00104-020-01172-0. Epub ahead of print.
    • Review, [Article in German]
    • AGA Clinical Practice Update on Pancreas Cancer Screening in High Risk Individuals: Expert Review.
    • Aslanian HR, Lee JH, Canto MI.
    • Gastroenterology. 2020 May 13:S0016-5085(20)30657-0. doi: 10.1053/j.gastro.2020.03.088. Epub ahead of print.
    • Review, Practice Guideline
    • Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
    • O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP.
    • J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.

    Related:

    Podcast, Research review: Optimizing Treatment Strategies for Germline BRCA/PALB2 Mutant Pancreatic Adenocarcinoma. (JCO Podcast. 2020 Jan 21.)

    Related:

    Letter, Comment:

    Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?

    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
    • BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.
    • Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA.
    • Cancer Manag Res. 2020 Apr 23;12:2731-2742. doi: 10.2147/CMAR.S211151. eCollection 2020.
    • Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    • Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, Halpern N, Brazowski E, Geva R, Wolf I, Goldes Y, Ben-Haim M, Klausner JM, Lubezky N.
    • Ann Surg Oncol. 2020 Apr 20. doi: 10.1245/s10434-020-08469-8. [Epub ahead of print]

    Related:

    Research review, Commentary:

    ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy.

    • New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    • Singh RR, O'Reilly EM.
    • Drugs. 2020 Apr 18. doi: 10.1007/s40265-020-01304-0. [Epub ahead of print]
    • Review
    • Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment.
    • Mukherjee S, Asaithamby A.
    • Transl Cancer Res. 2020 Apr;9(4):2154-2156. doi: 10.21037/tcr.2020.03.07.

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic.
    • [No author given]
    • GenomeWeb. 2020 Mar 30.
    • Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    • Gromisch C, Qadan M, Albuquerque Machado M, Liu K, Colson Y, Grinstaff MW.
    • Cancer Res. 2020 Mar 27:canres.2731.2019. doi: 10.1158/0008-5472.CAN-19-2731. Epub ahead of print.
    • Review
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging.
    • Morani AC, Hanafy AK, Ramani NS, Katabathina VS, Yedururi S, Dasyam AK, Prasad SR.
    • Radiol Imaging Cancer. 2020 Mar 13;2(2):e190020. doi: 10.1148/rycan.2020190020.
    • PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    • Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.
    • Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9.
    • Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    • Pazderová N, Urbán V, Makovník M, Macák D, Janega P, Chovanec M, Rejleková K, Mardiak J, Mego M.
    • Klin Onkol. 2020 Spring;33(3):220-225. English. doi: 10.14735/amko2020220.
    • The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    • Moffat GT, O'Reilly EM.
    • Clin Adv Hematol Oncol. 2020 Mar;18(3):168-179.
    • Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    • Christenson ES, Jaffee E, Azad NS.
    • Lancet Oncol. 2020 Mar;21(3):e135-e145. doi: 10.1016/S1470-2045(19)30795-8.
    • Review
    • Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
    • Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y.
    • Am J Transl Res. 2020 Feb 15;12(2):612-617. eCollection 2020.
    • An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    • Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM.
    • JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]
    • Review

    Related:

    Press: Pancreatic Cancer Patients May Harbor Treatable Germline Mutations. (Medscape Oncology)

    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • FDA Approves First PARP Inhibitor as Frontline Maintenance in Pancreatic Cancer.
    • Kahl KL.
    • Cancernetwork. 2019 Dec 30.
    • FDA Approves Myriad BRACAnalysis CDx for Lynparza in Metastatic Pancreatic Cancer.
    • [No author given]
    • Clinical OMICs. 2019 Dec 30.
    • FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer.
    • [No author given]
    • GenomeWeb. 2019 Dec 30.
    • New Option in Pancreatic Cancer: Olaparib for BRCA Mutations.
    • Chustecka Z.
    • Medscape Oncology. 2019 Dec 30.
    • LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • [No author given]
    • Merck. News Release. 2019 Dec 30.
    • Heartbreaking News, Then Tumor Find Leads to Genetic Testing.
    • Hackethal V.
    • Medscape Oncology. 2019 Dec 27.

    Related:

    Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, NCCN Guidelines Version 1.2020. (NCCN.org. 2019 Dec 4. Version 1.2020.)

    • Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients.
    • Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle M, Shroff RT, Varadhachary GR, Wolf RA, McAllister F, Futreal PA, Fogelman DR.
    • Clin Cancer Res. 2019 Dec 23. pii: clincanres.0224.2019. doi: 10.1158/1078-0432.CCR-19-0224. [Epub ahead of print]
    • PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
    • Patel R, Fein D, Ramirez CB, Do K, Saif MW.
    • Pancreas (Fairfax). 2019;3(1):e5-e8. doi: 10.17140/POJ-3-e011. Epub 2019 Dec 20.
    • NCCN Publishes Updated Genetic Risk Assessment Recommendations.
    • Wright K.
    • Cancernetwork. 2019 Dec 18.
    • Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications.
    • Gupta M, Iyer R, Fountzilas C.
    • Cancers (Basel). 2019 Dec 9;11(12). pii: E1980. doi: 10.3390/cancers11121980.
    • Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    • Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0582-7. [Epub ahead of print]

    Related:

    Editorial:

    Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.

    • Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
    • Lowery MA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0645-9. [Epub ahead of print]
    • From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
    • Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I.
    • Nat Rev Clin Oncol. 2019 Nov 8. doi: 10.1038/s41571-019-0281-6. [Epub ahead of print]
    • Review
    • Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
    • Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DPS, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin E 3rd.
    • JCO Precis Oncol. 2019 Dec [2019 Oct 23];3:1-10. doi: 10.1200/PO.19.00115.
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • Maintenance Olaparib for Metastatic Pancreatic Cancer.
    • Charkes ND.
    • N Engl J Med. 2019 Oct 10;381(15):1491. doi: 10.1056/NEJMc1911185.
    • Letter. Comment

    Related:

    Letter. Comment:

    Maintenance Olaparib for Metastatic Pancreatic Cancer.

    Reply:

    Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply.

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    • Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N.
    • Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.
    • PARP inhibition - opportunities in pancreatic cancer.
    • Pant S, Maitra A, Yap TA.
    • Nat Rev Clin Oncol. 2019 Oct;16(10):595-596. doi: 10.1038/s41571-019-0257-6.
    • Commentary

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    • Hammel P, Kindler HL, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T.
    • Ann Oncol. 2019 Sep 28. pii: mdz406. doi: 10.1093/annonc/mdz406. [Epub ahead of print]
    • Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    • Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N.
    • Cancer Treat Rev. 2019 Sep 6;80:101895. doi: 10.1016/j.ctrv.2019.101895. [Epub ahead of print]
    • Review
    • Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.
    • Elaileh A, Saharia A, Potter L, Baio F, Ghafel A, Abdelrahim M, Heyne K.
    • Am J Cancer Res. 2019 Sep 1;9(9):1871-1888. eCollection 2019.
    • Should PARP Inhibitors Have Tumor-Agnostic Approval Status?
    • Markman M.
    • Medscape Oncology. 2019 Aug 19.

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
    • Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G.
    • Oncologist. 2019 Aug 7. pii: theoncologist.2018-0905. doi: 10.1634/theoncologist.2018-0905. [Epub ahead of print]
    • Screening for Pancreatic Cancer.
    • Lucas AL, Kastrinos F.
    • JAMA. 2019 Aug 6;322(5):407-408. doi: 10.1001/jama.2019.9690.

    Related:

    Guidelines:

    Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement.

    Editorial:

    Screening for Pancreatic Cancer Gets a D, But the Student Is Improving.

    Editorial:

    Screening for Pancreatic Cancer-Is There Hope?

    • Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
    • Furuse J.
    • J Clin Med. 2019 Aug 4;8(8). pii: E1170. doi: 10.3390/jcm8081170.
    • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
    • N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

    Related:

    See PubMed abstract for multiple related items.

    • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
    • N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903387. [Epub ahead of print]

    Related:

    Research news: Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations. (FORCE. XRAYS.)

    Research news: Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (GenomeWeb)

    Research news: Olaparib Delays Progression in BRCA Pancreatic Cancer. (Medscape Oncology)

    Commentary, Research news: Should PARP Inhibitors Have Tumor-Agnostic Approval Status? (Medscape Oncology)

    • Pancreatic cancer in young adults: changes, challenges, and solutions.
    • Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D.
    • Onco Targets Ther. 2019 May 6;12:3387-3400. doi: 10.2147/OTT.S176700. eCollection 2019.
    • Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.
    • Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C.
    • Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):200-205. doi: 10.14701/ahbps.2019.23.2.200. Epub 2019 May 31.
    • Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
    • Kryklyva V, Haj Mohammad N, Morsink FHM, Ligtenberg MJL, Offerhaus GJA, Nagtegaal ID, de Leng WWJ, Brosens LAA.
    • Cancer Biol Ther. 2019 Apr 19:1-7. doi: 10.1080/15384047.2019.1595274. [Epub ahead of print]
    • Maintenance Rucaparib Controls Some Pancreatic Cancers.
    • [No authors listed]
    • Cancer Discov. 2019 Apr 2. doi: 10.1158/2159-8290.CD-NB2019-043. [Epub ahead of print]
    • PARP Inhibitors for Maintenance Therapy in Pancreatic Cancer?
    • Castellino AM.
    • Medscape. Medscape Oncology. 2019 Apr 2.

    Related:

    Conference abstract: CT234 - A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 (AACR Annual Meeting 2019)

    • Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation.
    • Yu S, Agarwal P, Mamtani R, Symecko H, Spielman K, O'Hara M, O'Dwyer PJ, Schneider C, Teitelbaum U, Nathanson KL, Domchek SM, Reiss KA.
    • JCO Precis Oncol. 2019 Dec [2019 Mar 28];3:1-11. doi: 10.1200/PO.18.00271.
    • Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    • Matsubayashi H, Takaori K, Morizane C, Kiyozumi Y.
    • Gut Liver. 2019 Mar 26. doi: 10.5009/gnl18449. [Epub ahead of print]
    • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    • Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM.
    • Cancer Treat Rev. 2019 Mar 22;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. [Epub ahead of print]
    • Review
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies.
    • Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L.
    • Cancers (Basel). 2019 Feb 7;11(2). pii: E193. doi: 10.3390/cancers11020193.
    • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Ohmoto A, Yachida S, Morizane C.
    • Int J Mol Sci. 2019 Jan 29;20(3). pii: E561. doi: 10.3390/ijms20030561.
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
    • Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.
    • Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.
    • Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    • Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B.
    • Pharmacogenomics. 2019 Jan;20(2):113-127. doi: 10.2217/pgs-2018-0073. Epub 2018 Dec 12.
    • Review
    • Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    • Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH.
    • Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.
    • Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    • Gleeson FC, Levy MJ.
    • Curr Treat Options Gastroenterol. 2018 Dec;16(4):441-448. doi: 10.1007/s11938-018-0195-x.
    • Review
    • Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
    • Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y.
    • ACS Nano. 2018 Nov 27;12(11):10785-10796. doi: 10.1021/acsnano.8b01573. Epub 2018 Nov 12.
    • Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    • Li M, Mou Y, Hou S, Cao D, Li A.
    • Medicine (Baltimore). 2018 Nov;97(45):e13113. doi: 10.1097/MD.0000000000013113.
    • My Father’s Fight Against the Breast-Cancer Gene.
    • Munster P.
    • The Wall Street Journal. The Saturday Essay. 2018 Sep 28.

    Related:

    Blog post: Pamela Munster's story: Cancer in the family (FORCE. XRAYS.)

    • Harnessing the Immune System in Pancreatic Cancer.
    • Das S, Berlin J, Cardin D.
    • Curr Treat Options Oncol. 2018 Aug 20;19(10):48. doi: 10.1007/s11864-018-0566-5.
    • Review
    • Emerging strategies in BRCA-positive pancreatic cancer.
    • Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D.
    • J Cancer Res Clin Oncol. 2018 Aug;144(8):1503-1507. doi: 10.1007/s00432-018-2666-9. Epub 2018 May 18.
    • Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    • Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.
    • Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.
    • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
    • Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.
    • Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.
    • Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
    • Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
    • Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
    • Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.
    • Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M.
    • Oncotarget. 2018 Apr 13;9(28):19817-19825. doi: 10.18632/oncotarget.24865. eCollection 2018 Apr 13.
    • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
    • O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.
    • Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.
    • BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    • Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J.
    • J Am Coll Surg. 2018 Apr;226(4):630-637.e1. doi: 10.1016/j.jamcollsurg.2017.12.021. Epub 2018 Jan 5.
    • Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy.
    • Shahda S, Timms KM, Ibrahim AA, Reid JE, Cramer HM, Radovich M, Ibrahim S, Allen B, O'Neil BH.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jan 19];2:1-11. doi: 10.1200/PO.17.00087.

    Related:

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.
    • Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jan 19];2:1-9. doi: 10.1200/PO.17.00152.

    Related:

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    • Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.
    • Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
    • Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    • Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.
    • Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
    • Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
    • Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.
    • Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    • Schmitt A, Feldmann G, Zander T, Reinhardt HC.
    • Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.
    • Risk factors, biomarker and imaging techniques used for pancreatic cancer screening.
    • Thomas C.
    • Chin Clin Oncol. 2017 Dec;6(6):61. doi: 10.21037/cco.2017.12.06.
    • Familial Pancreatic Cancer and the Future of Directed Screening.
    • Welinsky S, Lucas AL.
    • Gut Liver. 2017 Nov 15;11(6):761-770. doi: 10.5009/gnl16414.
    • Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.
    • Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, Klempner SJ.
    • JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.17.00043.
    • Family history of pancreatic cancer in BRCA1/2 testing criteria.
    • Toss A, Venturelli M, Pipitone S, Marchi I, Tenedini E, Medici V, Tagliafico E, Razzaboni E, Spaggiari F, De Matteis E, Cascinu S, Cortesi L.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi46. doi: 10.1093/annonc/mdx425.005.
    • DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
    • Golan T, Javle M.
    • J Natl Compr Canc Netw. 2017 Aug;15(8):1063-1069. doi: 10.6004/jnccn.2017.0133.
    • Review
    • Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer.
    • Yarchoan M, Myzak MC, Johnson Iii BA, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.
    • Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.
    • Hereditary pancreatic cancer: related syndromes and clinical perspective.
    • Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G.
    • Hered Cancer Clin Pract. 2017 Jun 28;15:9. doi: 10.1186/s13053-017-0069-6. eCollection 2017.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. [Presented Monday, June 5, 2017.] 2017;37:301-310. doi: 10.14694/EDBK_175222.
    • Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    • Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.
    • JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.
    • Verdaguer H, Saurí T, Macarulla T.
    • J Gastrointest Oncol. 2017 Jun;8(3):405-417. doi: 10.21037/jgo.2016.11.15.
    • BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.
    • Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Gong J, Zhong R, Huang K, Chang J, Miao X.
    • Oncotarget. 2017 May 30;8(22):36033-36039. doi: 10.18632/oncotarget.16422.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):301-310. doi: 10.1200/EDBK_175222.
    • Germline mutations in pancreatic cancer and potential new therapeutic options.
    • Pihlak R, Valle JW, McNamara MG.
    • Oncotarget. 2017 Apr 20;8(42):73240-73257. doi: 10.18632/oncotarget.17291. eCollection 2017 Sep 22.
    • BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    • Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.
    • Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.
    • Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    • Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.
    • Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.
    • Familial pancreatic cancer: Concept, management and issues.
    • Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T.
    • World J Gastroenterol. 2017 Feb 14;23(6):935-948. doi: 10.3748/wjg.v23.i6.935.
    • Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    • Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.
    • PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.
    • Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    • Lemstrova R, Melichar B, Mohelnikova-Duchonova B.
    • Cancer Chemother Pharmacol. 2016 Dec;78(6):1101-1111. Epub 2016 Jun 1.
    • Review
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Related:

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    • de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.
    • Endocr Relat Cancer. 2016 Oct;23(10):T57-T67. Epub 2016 Aug 10.

    Related:

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
    • Teo MY, O'Reilly EM.
    • J Gastrointest Oncol. 2016 Oct;7(5):738-749.
    • Insights on Hereditary Pancreatic Cancer.
    • Michael J Hall
    • FORCE. Be Empowered Webinars. 2016 Sep 6.
    • Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
    • Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH.
    • World J Gastroenterol. 2016 Aug 28;22(32):7275-88. doi: 10.3748/wjg.v22.i32.7275.
    • Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    • Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.
    • Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.
    • Review
    • Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    • Peters ML, Tseng JF, Miksad RA.
    • Clin Ther. 2016 Jul;38(7):1622-35. doi: 10.1016/j.clinthera.2016.03.006. Epub 2016 Apr 1.
    • Changing the course of pancreatic cancer - Focus on recent translational advances.
    • Javle M, Golan T, Maitra A.
    • Cancer Treat Rev. 2016 Mar;44:17-25. doi: 10.1016/j.ctrv.2016.01.004. Epub 2016 Jan 25.
    • Review
    • Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    • Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM.
    • Expert Opin Ther Targets. 2016 Mar;20(3):341-59. doi: 10.1517/14728222.2016.1094057. Epub 2015 Oct 6.
    • Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
    • Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii.
    • Letter

    Related:

    Case report

    Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

    Response / Letter

    The Authors Respond.

    • Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
    • Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T.
    • Med Oncol. 2016 Jan;33(1):4. doi: 10.1007/s12032-015-0720-x. Epub 2015 Dec 22.
    • The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
    • Martinez-Useros J, Garcia-Foncillas J.
    • Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18.
    • Diagnosis and Management of Hereditary Pancreatic Cancer.
    • Humphris JL, Biankin AV.
    • Recent Results Cancer Res. 2016;205:61-83. doi: 10.1007/978-3-319-29998-3_5.
    • Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report.
    • Yeung V, Palmer JD, Williams N, Weinstein JC, Fortuna D, Sama A, Winter J, Bar-Ad V.
    • Case Rep Pancreat Cancer. 2015 Nov 1;1(1):22-25. doi: 10.1089/crpc.2015.29003.vye. eCollection 2015.
    • Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
    • Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.
    • Case Rep Oncol. 2015 Oct 22;8(3):447-450. doi: 10.1159/000441414.
    • Pancreatic cancer: BRCA mutation and personalized treatment.
    • Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X.
    • Expert Rev Anticancer Ther. 2015 Oct;15(10):1223-31. doi: 10.1586/14737140.2015.1086271. Epub 2015 Sep 7.
    • Review
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Related:

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
    • Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G.
    • Cancer Lett. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.
    • BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
    • Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.
    • Br J Cancer. 2015 Jul 28;113(3):425-432. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.
    • Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
    • Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW.
    • Anticancer Drugs. 2015 Feb;26(2):224-6. doi: 10.1097/CAD.0000000000000178.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Related:

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
    • Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.
    • Br J Cancer. 2014 Sep 9;111(6):1132-1138. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.
    • PARP-Inhibitors in BRCA-Associated Pancreatic Cancer.
    • Bhalla A, Saif MW.
    • JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA and Pancreatic Cancer.
    • Brennan GT, Relias V, Saif MW.
    • JOP. 2013 Jul 10;14(4):325-8. doi: 10.6092/1590-8577/1652.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    • Partensky C.
    • Pancreas. 2013 Jul;42(5):729-39. doi: 10.1097/MPA.0b013e318288107a.
    • Review
    • PARP Inhibitors Hold Promise in Pancreas Cancer.
    • Eileen O'Reilly.
    • Medscape Medical News. Medscape Oncology. 2013 Annual Meeting of the American Society of Clinical Oncology. 2013 Jun 17.
    • Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
    • Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A.
    • Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29.
    • BRCA-associated pancreatic cancer: the evolving management.
    • Leung K, Saif MW.
    • JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Related:

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • BRCA and pancreatic cancer: selection of chemotherapy.
    • Kim R, Byer J, Saif MW.
    • JOP. 2012 Mar 10;13(2):180-1.